FORMULATION DEVELOPMENT AND EVALUATION OF ANTI-DIABETIC ACTIVITY OF POLYHERBAL TABLET IN STREPTOZOTOCIN INDUCED DIABETIC RATS

Abstract

Objective: The current research work emphasized on the formulation development and evaluation of polyherbal antidiabetic tablet containing Terminalia catappa, Costus igneus, and Cassia fistula in streptozotocin-induced diabetic rats.

Method: The study evaluated a polyherbal blend in Albino Wistar rats (150–200 g) through acute toxicity, OGTT, and antidiabetic activity, with a focus on formulating a polyherbal tablet. Diabetes was induced using streptozotocin (60 mg/kg). Over 28 days, 13 groups were observed: normal, diabetic control, standard treatment (Glibenclamide 5 mg/kg), and various doses of the polyherbal blend at 200 mg/kg and 400 mg/kg. Blood samples were collected via retro orbital puncture on days 7, 14, 21, and 28 to assess blood glucose levels, body weight changes, and profiles of liver, lipids, and kidneys, along with histopathological improvements post-treatment.

Results: The polyherbal blend PHB-2B (TC: CI: CF: 2: 1: 1) exhibited optimal blood glucose levels and enhanced body weight in diabetic rats. It also significantly reduced total cholesterol, improved lipid profiles (increased HDL, decreased LDL and VLDL), and enhanced liver and kidney functions. For tablet formulation optimization, PHB 2B was selected, with formulation PHT7 demonstrating the best pre and post-evaluation outcomes among the nine formulations (PHT1-PHT9).

Conclusion: Formulation PHT 7 demonstrates significant antidiabetic benefits and safeguards biochemical and histological markers, indicating its safety and effectiveness in vivo. It presents a secure and practical alternative for diabetes management, leveraging Ayurvedic components to offer new potential in treating lifestyle diseases.